Related by context. All words. (Click for frequent words.) 72 pancreatic adenocarcinoma 70 nonsmall cell lung cancer 69 hepatorenal syndrome 69 peritoneal cancer 69 metastatic gastric 68 squamous histology 68 leukemia AML 68 thymoma 68 nonmelanoma skin cancers 68 peritoneal carcinomatosis 67 lymphocytic leukemia 67 lung metastases 67 Hepatocellular Carcinoma HCC 67 malignant neoplasm 67 endometrial hyperplasia 67 liver metastases 67 AGILECT R 67 candidemia 67 metastatic bladder 67 prostate carcinoma 67 curative resection 67 chemoradiotherapy 67 malignant pleural mesothelioma 67 recurrent glioblastoma multiforme 66 advanced adenoma 66 invasive aspergillosis 66 preoperative chemotherapy 66 follicular lymphoma FL 66 grade gliomas 66 smoldering myeloma 66 carcinoid tumors 66 renal cell carcinomas 66 nonmetastatic 66 FOLFOX4 66 squamous cell lung cancer 66 KRAS mutations occur 66 cisplatin chemotherapy 66 HNSCC 66 ER CHOP 66 mycophenolate mofetil 66 nonsquamous 66 colorectal liver metastases 66 thymic carcinoma 65 intravenous bisphosphonates 65 resected pancreatic cancer 65 allogeneic HSCT 65 distant metastases 65 locoregional 65 Adjuvant chemotherapy 65 histologic subtype 65 mutated KRAS 65 relapsed MM 65 Doxil ® 65 gastrointestinal stromal tumor 65 adjuvant radiotherapy 65 metastatic adenocarcinoma 65 medically inoperable 65 CYPHER Stent 65 acute myelogenous leukemia AML 65 follicular lymphomas 65 seminoma 65 systolic dysfunction 65 mesotheliomas 65 IV NSCLC 65 papillary carcinoma 65 metastatic RCC 65 metastatic colon cancer 65 CP CPPS 65 docetaxel chemotherapy 65 pegylated liposomal doxorubicin 65 hepatic metastases 65 papillary renal cell carcinoma 65 gemcitabine chemotherapy 65 Wilms tumors 65 unresectable tumors 65 PASI scores 65 MALT lymphoma 65 MGUS 65 carcinoid 65 ductal breast cancer 65 operable breast cancer 65 lupus nephritis 65 unresectable stage 65 stage IIIB IV 65 underwent resection 64 prostate cancer CaP 64 renal carcinoma 64 renal tumors 64 pancreatic carcinoma 64 fallopian tube carcinoma 64 haematologic 64 cervical carcinoma 64 adjuvant radiation 64 thoracoscopic lobectomy 64 GISTs 64 bronchogenic carcinoma 64 gross hematuria 64 acute leukemias 64 dacarbazine chemotherapy 64 sorafenib Nexavar 64 DFMO 64 liver metastasis 64 idraparinux 64 EXJADE 64 angiosarcoma 64 metastatic renal cell carcinoma 64 neoplasias 64 TTF Therapy 64 heavily pretreated 64 Hurthle cell 64 CMV disease 64 recurrent glioblastoma 64 neoadjuvant therapy 64 EUS FNA 64 liposomal amphotericin B 64 advanced adenomas 64 androgen deprivation 64 IV bisphosphonates 64 metastatic malignant melanoma 64 interferon ribavirin 64 basiliximab 64 gefitinib Iressa 64 AA Amyloidosis 64 concurrent chemoradiation 64 intravesical therapy 64 myeloid leukemia 64 squamous cell cancer 64 invasive fungal infection 64 cytoreduction 64 HSCT 64 aldosterone antagonist 64 Lung transplantation 64 trabectedin 64 invasive carcinoma 64 mRCC 64 underwent surgical resection 64 nasopharyngeal carcinoma 64 decitabine 64 HBeAg positive patients 64 glycated hemoglobin levels 64 pamidronate 64 biochemical relapse 64 medullary thyroid cancer 64 postoperative pulmonary 64 lung metastasis 64 5-FU/LV 63 bladder cancers 63 juvenile myelomonocytic leukemia 63 underwent liver transplantation 63 TNF antagonist 63 QTc prolongation 63 sorafenib 63 Velcade bortezomib 63 cediranib 63 thalidomide Thalomid 63 NMIBC 63 polyp recurrence 63 adrenalectomy 63 complete cytogenetic response 63 portal vein thrombosis 63 alveolar rhabdomyosarcoma 63 mcg albinterferon alfa 2b 63 HBeAg negative 63 non squamous NSCLC 63 hepatectomy 63 leukemia ALL 63 Glioblastoma Multiforme 63 HIV HCV coinfected 63 ischemic cardiomyopathy 63 HER2 positive cancers 63 differentiated thyroid 63 minimally symptomatic 63 resectable 63 recurrent metastatic 63 chemoradiation therapy 63 standard chemotherapy regimen 63 bile duct cancers 63 BARACLUDE ® 63 grade cervical intraepithelial 63 Glioblastoma Multiforme GBM 63 postoperative chemotherapy 63 neuroendocrine carcinoma 63 recurrent VTE 63 GIST tumors 63 TORISEL 63 colorectal adenoma 63 radioiodine therapy 63 Waldenstrom macroglobulinemia 63 lumbar disk herniation 63 preserved ejection fraction 63 CIMZIA ™ 63 relapsed AML 63 pancreatic resection 63 soft tissue sarcomas 63 PSADT 63 intestinal metaplasia 63 placebo dexamethasone 63 symptomatic VTE 63 GnRH agonists 63 seropositive patients 63 hepatic encephalopathy HE 63 atypical hemolytic uremic syndrome 63 lenalidomide Revlimid R 63 myelogenous leukemia 63 urothelial cancer 63 cholangiocarcinoma 63 recurrent NSCLC 63 Wegener granulomatosis 63 ischemic colitis 63 ADPKD 63 nondiabetic patients 63 clodronate 63 radical nephrectomy 63 cranial radiation 63 pCR 63 LVNC 63 carcinoid cancer 63 histological subtype 63 metastatic colorectal 63 prostate adenocarcinoma 63 hepatocellular carcinomas 63 refractory AML 63 superficial bladder cancer 63 interstitial pneumonia 63 metastatic renal cell 63 GBM tumors 63 gastrointestinal malignancies 63 Chronic lymphocytic leukemia 63 octreotide LAR 63 infliximab Remicade 63 Folfox 63 severe exacerbations 63 adenomatous 63 skeletal metastases 63 corticosteroid therapy 63 rindopepimut 63 metastatic kidney 63 FluCAM arm 63 chemoradiation 63 CTEPH 63 serum phosphate 62 INCB# [003] 62 isolated systolic hypertension 62 Surgical resection 62 Torisel 62 rFVIIa 62 glioblastoma brain tumor 62 epithelial tumors 62 cytoreductive surgery 62 node metastases 62 lung adenocarcinomas 62 sleeve lobectomy 62 carcinoid tumor 62 basal cell carcinoma BCC 62 NSCLC 62 ruboxistaurin 62 serous ovarian cancer 62 radiochemotherapy 62 hemodialysis patients 62 heavily pretreated patients 62 basal cell nevus syndrome 62 osteosarcomas 62 HER2 overexpression 62 metastatic uveal melanoma 62 ependymoma 62 Adjuvant therapy 62 gastrointestinal stromal tumor GIST 62 advanced unresectable 62 chemotherapeutic regimens 62 intra arterial chemotherapy 62 thrombocytopenic 62 metastatic ovarian cancer 62 metastatic malignant 62 neutropenic 62 non metastatic osteosarcoma 62 chemoembolization 62 Papillary 62 gallium nitrate 62 mycophenolate 62 adriamycin 62 pulmonary metastases 62 5-fluorouracil/leucovorin 62 colorectal lung 62 SCCHN 62 advanced medullary thyroid 62 IFN beta 62 T1c 62 oral clodronate 62 stage IIIA 62 penicillin allergy 62 NATRECOR ® 62 caspofungin 62 lymphocytosis 62 mTOR inhibitors 62 allogeneic stem cell 62 Xelox 62 idiopathic pulmonary fibrosis IPF 62 neoadjuvant chemotherapy 62 colorectal cancer CRC 62 lobular cancer 62 precancerous cervical lesions 62 parathyroidectomy 62 postoperative complication 62 astrocytoma 62 lung fibrosis 62 Hodgkin lymphoma HL 62 untreated chronic lymphocytic 62 lymph node metastases 62 acute lymphoblastic 62 cabazitaxel 62 gastric adenocarcinoma 62 Postoperative complications 62 prognostic variables 62 ZACTIMA 62 colorectal cancer liver metastases 62 pilocytic astrocytoma 62 amoxicillin clavulanate 62 nutlin 3a 62 systemic corticosteroid 62 chronic granulomatous disease 62 gastric cancers 62 elevated ALT 62 PSMA ADC 62 total abdominal hysterectomy 62 inoperable pancreatic cancer 62 deep venous thromboses 62 oropharyngeal cancer 62 proliferative diabetic retinopathy 62 eosinophilic pneumonia 62 posaconazole 62 anthracycline taxane 62 KRAS mutant tumors 62 leiomyosarcoma 62 RSD# oral 62 androgen ablation 62 ELOXATIN 62 H. pylori eradication 62 Cytoxan 62 antimicrobial prophylaxis 62 unresectable 62 postoperative mortality 62 recurrent GBM 62 metastatic GIST 62 receiving VICTRELIS 62 Uricase PEG 62 acute aortic dissection 62 esophageal carcinoma 62 docetaxel Taxotere 62 serum creatinine levels 62 perioperative morbidity 62 LHRH receptor positive 62 docetaxel Taxotere ® 62 esophageal candidiasis 62 pediatric acute lymphoblastic 62 ovarian malignancy 62 esophageal cancers 62 clinically detectable 62 pleural mesothelioma 62 SCIg 62 histologically confirmed 62 antiangiogenic therapy 62 lymph node involvement 62 visceral metastases 62 CMV infection 62 methotrexate therapy 62 CYT# potent vascular disrupting 62 teriflunomide 61 embryonal rhabdomyosarcoma 61 type 1diabetes 61 CTAP# Capsules 61 diabetic kidney 61 prostate cancer CRPC 61 LHRH agonists 61 pemphigus vulgaris 61 stage IIIb 61 HER2 positive metastatic breast 61 keloid scarring 61 symptomatic aortic stenosis 61 relapsed SCLC 61 vWD 61 standard chemotherapy regimens 61 tumor recurrence 61 canakinumab 61 Fanconi syndrome 61 locoregional recurrence 61 graft occlusion 61 distant metastasis 61 LV dysfunction 61 invasive candidiasis 61 myeloproliferative disorders 61 MYDICAR 61 therapeutic regimens 61 recurrent malignant glioma 61 PCNSL 61 ofpatients 61 advanced neoplasia 61 TNF blocker therapy 61 biliary tract cancer 61 bronchopulmonary dysplasia 61 peginterferon 61 Eculizumab 61 elevated LDH 61 Renal Cell Carcinoma RCC 61 acute STEMI 61 sorafenib Nexavar ® 61 pheochromocytoma 61 invasive ductal 61 bleomycin 61 renal biopsy 61 metastatic prostate cancer 61 hypercalcemia 61 tumor histology 61 paraganglioma 61 invasive lobular carcinoma 61 Myelodysplastic Syndrome 61 Follicular Lymphoma 61 tigecycline 61 metastatic cancer 61 T1DM 61 systemic scleroderma 61 mycosis fungoides 61 metastatic disease 61 neoadjuvant treatment 61 antithrombotic therapy 61 efalizumab 61 alemtuzumab treated 61 thrombocytosis 61 liver resection 61 Heavy menstrual bleeding 61 macroalbuminuria 61 invasive fungal infections 61 evaluating tivozanib 61 pancreatic lung 61 nasopharyngeal cancer 61 myelodysplastic syndrome MDS 61 renal cell carcinoma 61 KRAS status 61 perioperative complications 61 ALI ARDS 61 nonalcoholic steatohepatitis 61 stage IIIb IV 61 gastric carcinoma 61 Nexavar sorafenib 61 deferiprone 61 neuroendocrine tumors 61 PREZISTA r arm 61 #F FDG PET 61 squamous cell carcinoma SCC 61 cilengitide 61 anthracyclines taxanes 61 paricalcitol 61 PNH patients 61 nodal metastasis 61 AML MDS 61 calcineurin inhibitors 61 hematologic toxicity 61 anterior uveitis 61 infective endocarditis 61 Radical prostatectomy 61 endocrine therapies 61 anemia hemoglobin 61 mycophenolate mofetil MMF 61 atypical hyperplasia 61 squamous 61 Subgroup analysis 61 pomalidomide 61 chorioamnionitis 61 Myelodysplastic Syndrome MDS 61 benign polyps 61 diabetes mellitus DM 61 cerebral vasospasm 61 Thrombocytopenia 61 CR nPR 61 intra abdominal abscess 61 Medullary thyroid cancer 61 Kaplan Meier analysis 61 imipenem 61 childhood acute lymphoblastic 61 interferon therapy 61 localized renal 61 chlorambucil 61 ertapenem 61 relapsed ALL 61 infusional 5-FU/LV 61 perioperatively 61 endosonography 61 neurologic complications 61 aldosterone antagonists 61 de novo AML 61 Thal Dex 61 chronic renal disease 61 Fludara 61 pT2 61 post thrombotic syndrome 61 myelofibrosis MF 61 hamartomas 61 ANCA associated 61 stage IIIB 61 lung cancer NSCLC 61 anti angiogenic agents 61 immunosuppressive therapies 61 atypical ductal hyperplasia 61 idarubicin 61 breast carcinomas 61 diffuse gastric 61 malignant lymphoma 61 fluvastatin 61 Gleevec resistant 61 perioperative mortality 61 Flu Cy 61 sargramostim 61 invasive ductal breast cancer 61 total thyroidectomy 61 graft dysfunction 61 underwent CABG 61 Zevalin consolidation 61 relapsing remitting MS RRMS 61 androgen suppression 61 SSc 61 Hodgkin lymphoma NHL 61 metastatic carcinoid tumors 61 ximelagatran 61 gastrointestinal perforation 61 AEG# 61 Cloretazine 61 definite stent thrombosis 61 Dacogen decitabine 61 IOP lowering 61 autologous transplants 61 brain metastases 61 nephrotoxicity 61 vismodegib 61 curable cancers 61 proliferative retinopathy 61 fulvestrant 61 adecatumumab 61 relapsing MS 61 MAGE A3 ASCI 61 irinotecan chemotherapy 61 paclitaxel Taxol R 61 postoperative delirium 61 precancerous condition 61 noninfectious uveitis 61 prostate cancer PCa 61 malignant ascites 61 intracerebral hemorrhage 61 GnRH agonist 61 Hashimoto thyroiditis 61 pertuzumab 61 decompensated cirrhosis 61 RAS mutations 61 smoldering multiple myeloma 61 Degarelix 61 KRAS wild 61 baseline LDH 61 CRVO 61 adjuvant therapies 61 undergone radical prostatectomy 61 neutropenic patients 61 immunomodulatory therapy 61 Reverset 61 carcinoids 61 intraductal 61 folinic acid 61 chronic rhinosinusitis 61 orchitis 61 chemotherapy cisplatin 61 interstitial pneumonitis 61 IV melanoma 61 lung resection 60 imatinib Gleevec 60 K ras mutations 60 chronic HCV 60 methotrexate monotherapy 60 Wilm tumor 60 VFEND 60 mg/m2 dose 60 non squamous 60 acid suppressive medications 60 Acute Myelogenous Leukemia 60 Pemetrexed 60 liposarcoma 60 BRIM2 60 non resectable metastatic 60 biochemical recurrence 60 β blockers 60 neurodevelopmental impairment 60 fluorouracil leucovorin 60 recurrent UTI 60 PROCHYMAL 60 rituximab Rituxan 60 abacavir Ziagen 60 thrombotic complications 60 TMP SMX 60 Chronic Myelogenous Leukemia CML 60 thymectomy 60 epithelial ovarian cancer 60 oral squamous cell 60 Acute Myeloid Leukaemia AML 60 evaluable subjects 60 hepatic toxicity 60 fallopian tube cancers 60 osteoporotic vertebral compression fractures 60 castration resistant prostate cancer 60 salmeterol fluticasone 60 colorectal carcinoma 60 calcineurin inhibitor 60 erythema nodosum 60 iniparib 60 sunitinib 60 contralateral breast 60 Chronic Lymphocytic Leukemia CLL 60 dacarbazine DTIC 60 Pseudomonas aeruginosa infections 60 gastrointestinal cancers 60 prostate cancer HRPC 60 urothelial carcinoma 60 gastroesophageal junction 60 eculizumab therapy 60 relapsed leukemia 60 pancreatic NET 60 hormone receptor negative 60 immunocompetent 60 thromboembolic disease 60 castrate resistant 60 infantile hemangiomas 60 cutaneous melanoma 60 Atrasentan 60 achieved CCyR 60 untreated AML 60 dasatinib 60 COPD exacerbation 60 systemic amyloidosis 60 bowel resection 60 revascularization procedures 60 azacitidine 60 cranial irradiation 60 nonmalignant 60 micafungin 60 melanoma lesions 60 HBV infections 60 thyroid carcinoma 60 plasminogen activators 60 capecitabine Xeloda R 60 Aortic stenosis 60 PD LID 60 febrile neutropenia 60 figitumumab 60 neurologic sequelae 60 variceal hemorrhage 60 surgically resectable 60 hsCRP levels 60 severe neutropenia 60 acute myeloid 60 endometrial carcinoma 60 postoperative infection 60 pouchitis 60 PAOD 60 hypophosphatemia 60 indolent lymphoma 60 refractory acute myeloid 60 urethral stricture 60 MGd 60 cytogenetic responses 60 Synovial sarcoma 60 BCR ABL inhibitor 60 posttransplant 60 inhaled cyclosporine 60 delayed CINV 60 postoperative atrial fibrillation 60 familial pancreatic cancer 60 familial ALS 60 dexpramipexole 60 transfusion syndrome 60 dasatinib Sprycel 60 asymptomatic carotid stenosis 60 anagrelide 60 Certolizumab pegol 60 cutaneous squamous cell carcinoma 60 ALT flares 60 steroid dexamethasone 60 PREZISTA r 60 ELACYT 60 rheumatologic 60 zoster 60 pretransplant 60 polycystic kidneys 60 chronic HBV 60 % CI #.#-#.# [007] 60 breast endometrial 60 Tumors shrank 60 allogeneic bone marrow 60 abacavir lamivudine 60 sulfasalazine 60 laparoscopically assisted 60 LNG IUS 60 idiopathic PAH 60 hepatitis C genotype 60 ACTEMRA TM 60 epithelial ovarian 60 primary hyperparathyroidism 60 EGFRIs 60 S. aureus infection 60 erlotinib Tarceva ® 60 Stent thrombosis 60 squamous cell histology 60 Hurler syndrome 60 esophagectomy 60 maximally tolerated lipid lowering 60 pancreatic cancers 60 clinically localized prostate 60 p# biomarker 60 pulmonary metastasis 60 adrenocortical cancer 60 budesonide foam 60 ovarian carcinoma 60 femoral neck fracture 60 sustained ventricular tachycardia 60 cetuximab Erbitux 60 primary immunodeficiency PI 60 colorectal neoplasms 60 IPAH 60 BRAF mutations 60 CIN3 60 chronic GVHD 60 trastuzumab Herceptin ® 60 acute leukemia AML 60 relapsed GBM 60 sorafenib tablets 60 chemoresistant 60 anaplastic 60 malignant glioma brain tumor 60 allogeneic transplant 60 erlotinib Tarceva 60 refractory NSCLC 60 lymphangioleiomyomatosis LAM 60 beta blocker therapy 60 MYCN amplification 60 neuroendocrine cancers 60 Hydroxyurea 60 thrombocytopenic patients 60 Cholangiocarcinoma 60 RET PTC rearrangements 60 lenalidomide dexamethasone 60 juvenile idiopathic arthritis 60 Subgroup analyzes 60 hydroxychloroquine 60 #mg ATC 60 riociguat 60 metastatic lesion 60 recurrent genital herpes 60 cancer mCRC 60 resistant hormone refractory 60 serum calcium levels 60 Myelodysplasia 60 Metastatic breast cancer 60 postoperative morbidity 60 cisplatin resistant 60 Neurofibromatosis type 60 ductal carcinomas 60 interstitial pulmonary fibrosis 60 leukemia CLL 60 temsirolimus 60 leukaemias 60 patients evaluable 60 monoclonal gammopathy 60 malignant neoplasms 60 antithymocyte globulin 60 liver histology 60 Radiofrequency ablation 60 lymphoblastic leukemia 60 mCRC patients 60 gastrointestinal stromal tumors GIST 60 biologic DMARD 60 imatinib resistance 60 NOMID 60 CMV infections 60 EGFR mutation positive 60 samalizumab 60 forodesine 60 comparator arm 60 acute promyelocytic leukemia 60 benign nodules 60 HbA 1c levels 60 coinfected patients 60 ruptured aneurysms 60 oesophageal adenocarcinoma 60 nephrosis 60 myelofibrosis 60 unstable angina UA 60 Gemzar ® 60 MELD scores 60 amphotericin B 60 Jevtana 60 Perforomist Inhalation Solution 60 breast carcinoma 60 severe aplastic anemia 60 paroxysmal AF 60 talabostat 60 neuroblastoma tumor 60 basal cell cancers 60 juvenile idiopathic arthritis JIA 60 cryptogenic 60 pain palliation 60 basal bolus regimen 60 severe mitral regurgitation 60 precursor lesions 60 metastatic renal 60 pT3 60 FDG PET imaging 60 intestinal polyps 60 BCIRG 60 visilizumab 60 allogeneic hematopoietic stem cell 60 argatroban 60 Ribavirin causes 60 metastatic neuroendocrine tumors 60 antiretroviral naïve 60 immunomodulatory agents 60 hormone refractory metastatic prostate 60 chemotherapeutic regimen 60 postoperative pathology 60 diffuse intrinsic pontine glioma 60 EndoTAGTM 1 60 androgen suppression therapy 60 bilateral oophorectomy 60 lung resections 60 binary restenosis 60 invasive ductal carcinoma 60 benign prostatic hypertrophy BPH 60 Gliadel Wafer 60 carotid stenosis 60 serum urate levels 60 retrospective cohort 60 myelodysplasia 60 ibandronate 60 BENICAR HCT 60 Inhaled nitric oxide 59 palliative radiotherapy 59 pancreatectomy 59 Eisenmenger syndrome 59 Staphylococcus aureus infections 59 clomipramine 59 FOLFIRINOX 59 plus gemcitabine 59 complete remissions 59 pancreatic insufficiency 59 SHPT 59 KRAS oncogene 59 oral antidiabetic agents 59 lobular carcinoma 59 TEMODAL 59 diverticular bleeding 59 intracranial hemorrhage ICH 59 adjuvant therapy 59 variceal bleeding 59 morphometric vertebral fractures 59 percutaneous biopsy 59 Natalizumab 59 Tavocept 59 biliary cancer 59 hormone deprivation 59 gemcitabine carboplatin 59 erlotinib 59 reoperations 59 TAXOTERE ® 59 ALND 59 carboplatin paclitaxel 59 YONDELIS 59 dopaminergic therapy 59 anthracycline chemotherapy 59 hepatoblastoma 59 tipranavir ritonavir 59 ductal lobular 59 MCyR 59 pre cancerous lesion 59 topotecan 59 RRMS patients 59 malignant brain 59 Squamous 59 HBeAg negative patients 59 prior chemotherapy regimens 59 follicular NHL 59 systemic ALCL 59 EDSS scores 59 Sentinel node biopsy 59 cinacalcet 59 essential thrombocythemia 59 elevated transaminases 59 intermittent dosing 59 clinically evaluable 59 Wilms tumor 59 KRAS mutation 59 PSA nadir 59 ankylosing spondylitis AS 59 estramustine 59 vandetanib 59 grade glioma 59 mildly symptomatic 59 Bloodstream infections 59 curative therapy 59 virological failure 59 multimodality therapy 59 S. aureus infections 59 refractory indolent non 59 HIPEC 59 benign proliferative breast 59 tuberculin skin testing 59 terlipressin 59 homozygous familial hypercholesterolemia 59 laryngeal cancer 59 autologous transplantation 59 complete cytogenetic 59 pharmacokinetic interactions 59 Rectal cancer 59 platinum refractory 59 Riluzole 59 sustained virologic response 59 APOL1 59 Acute myeloid leukemia 59 retransplantation 59 castration resistant 59 VaD 59 pathologic fractures 59 paclitaxel cisplatin 59 carcinoma HCC 59 cholinesterase inhibitor 59 GRNCM1 59 hematologic parameters 59 vaccinees 59 indolent NHL 59 transplantation HCT 59 Hazard Ratio 59 duodenal ulcer 59 symptomatic paroxysmal AF 59 taxane refractory 59 chronic periodontitis 59 everolimus eluting stents 59 neoadjuvant 59 distal colon cancer 59 splenectomized 59 revascularization procedure 59 intravenous diuretics 59 oophorectomy 59 precancer 59 anti angiogenic therapy 59 imatinib therapy 59 Tarceva TM 59 virologic failure 59 galiximab 59 autoantibody positive 59 premalignant lesions 59 VADT 59 Gastric cancer 59 pediatric malignancies 59 malignant pleural effusion 59 adjuvant cisplatin 59 bacteriuria 59 Hypotension 59 retinal vein occlusion 59 Adenomas 59 relapsed ovarian cancer 59 radicular pain 59 immune reconstitution 59 metastatic CRC 59 MIRAPEX 59 glioblastoma 59 ductal cancer 59 idiopathic thrombocytopenic purpura ITP 59 Febrile neutropenia 59 Kantarjian 59 STRIDE PD 59 neuroblastomas 59 colectomy 59 complement inhibitor eculizumab 59 intraperitoneal therapy 59 Toxicities 59 Wilms Tumor 59 Legg Calvé Perthes disease 59 chronic renal insufficiency 59 alcoholic hepatitis 59 APTIVUS r 59 decompensated heart failure 59 mCRC acneform rash 59 ticlopidine 59 nonmelanoma 59 mL/min/#.# m 2 59 resectable pancreatic cancer 59 Pamidronate 59 pituitary adenomas 59 spontaneous bacterial peritonitis 59 dosing cohort 59 neoplastic cells 59 % CI #.#-#.# [003] 59 nephrectomy 59 FVIII inhibitors 59 completely resected 59 autologous SCT 59 patients undergoing CABG